Plant Name: Croton tiglium
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; | |
| FAAH; TDP1; TERT; HPGD; AKR1B1; AKR1B10; ALOX15; ALDH1A1; | |
| PRKCE; PRKCB; PRKCG; PRKCD; PRKCQ; PRKCH; PRKCA; | |
| PPARA; PPARD; PPARG; | |
| NR1I2; | |
| PTGS1; PTGS2; | |
| TLR2; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | PRKCE | Protein kinase C epsilon | Q02156 | CHEMBL3582 |
| Protein Kinase | PRKCB | Protein kinase C beta | P05771 | CHEMBL3045 |
| Protein Kinase | PRKCG | Protein kinase C gamma | P05129 | CHEMBL2938 |
| Protein Kinase | PRKCD | Protein kinase C delta | Q05655 | CHEMBL2996 |
| Protein Kinase | PRKCQ | Protein kinase C theta | Q04759 | CHEMBL3920 |
| Protein Kinase | PRKCH | Protein kinase C eta | P24723 | CHEMBL3616 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 2.827E-09 | 4.397E-06 | FABP3, FFAR1, PPARG, PRKCE, PTGS2, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0004699; calcium-independent protein kinase C activity | 3.743E-09 | 5.094E-06 | PRKCD, PRKCE, PRKCH |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 6.464E-09 | 7.819E-06 | PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ |
| MF | GO:0003824; catalytic activity | GO:0004698; calcium-dependent protein kinase C activity | 1.495E-08 | 1.192E-05 | PRKCA, PRKCB, PRKCG |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.705E-08 | 3.476E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0034351; negative regulation of glial cell apoptotic process | 2.085E-07 | 8.406E-05 | PRKCA, PRKCD, PRKCH |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 6.242E-07 | 1.972E-04 | LMNA, PPARD, PRKCE, PTGS2, TERT |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 8.155E-07 | 2.466E-04 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, CYP3A4, HPGD, PPARD, PPARG, PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.029E-06 | 2.948E-04 | FFAR4, PPARA, PPARD, PPARG, PRKCD |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.093E-06 | 3.052E-04 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.067E-06 | 5.114E-04 | ALOX15, HPGD, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.322E-06 | 5.619E-04 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0035408; histone H3-T6 phosphorylation | 2.493E-06 | 5.836E-04 | PRKCA, PRKCB |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.493E-06 | 5.836E-04 | PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0035403; histone kinase activity (H3-T6 specific) | 2.493E-06 | 5.836E-04 | PRKCA, PRKCB |
| BP | GO:0009987; cellular process | GO:0090330; regulation of platelet aggregation | 3.005E-06 | 6.772E-04 | PRKCA, PRKCD, PRKCQ |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 3.876E-06 | 8.525E-04 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0050996; positive regulation of lipid catabolic process | 5.646E-06 | 1.171E-03 | PPARA, PRKCD, PRKCE |
| MF | GO:0005488; binding | GO:0008144; drug binding | 7.137E-06 | 1.388E-03 | CYP3A4, NR1I2, PPARA, PPARD, PPARG, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ |
| BP | GO:0032501; multicellular organismal process | GO:0032613; interleukin-10 production | 7.471E-06 | 1.415E-03 | PRKCD, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 7.471E-06 | 1.415E-03 | ALOX15, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0046627; negative regulation of insulin receptor signaling pathway | 1.476E-05 | 2.380E-03 | PRKCB, PRKCD, PRKCQ |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 2.485E-05 | 3.602E-03 | PPARA, PPARG |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 3.724E-05 | 4.975E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 3.724E-05 | 4.975E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 3.724E-05 | 4.975E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 3.724E-05 | 4.975E-03 | FABP3, PPARG |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.251E-05 | 5.543E-03 | AKR1B1, AKR1B10, CYP3A4, NR1I2, PPARD |
| BP | GO:0009987; cellular process | GO:0007077; mitotic nuclear envelope disassembly | 4.741E-05 | 6.037E-03 | LMNA, PRKCA, PRKCB |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 4.741E-05 | 6.037E-03 | AKR1B1, AKR1B10, ALDH1A1 |
| BP | GO:0009987; cellular process | GO:0050861; positive regulation of B cell receptor signaling pathway | 5.209E-05 | 6.444E-03 | PRKCB, PRKCH |
| MF | GO:0003824; catalytic activity | GO:0001758; retinal dehydrogenase activity | 5.209E-05 | 6.444E-03 | AKR1B10, ALDH1A1 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.353E-05 | 6.549E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0031328; positive regulation of cellular biosynthetic process | 5.951E-05 | 7.199E-03 | FABP3, NR1I2, PPARA, PPARD, PPARG, PRKCD, PRKCQ, PTGS2, TERT, TLR2, TSHR |
| BP | GO:0008152; metabolic process | GO:0044597; daunorubicin metabolic process | 6.938E-05 | 8.005E-03 | AKR1B1, AKR1B10 |
| BP | GO:0008152; metabolic process | GO:0044598; doxorubicin metabolic process | 6.938E-05 | 8.005E-03 | AKR1B1, AKR1B10 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 6.948E-05 | 8.005E-03 | FABP3, PPARA, PPARG, TLR2 |
| BP | GO:0065007; biological regulation | GO:0051092; positive regulation of NF-kappaB transcription factor activity | 7.144E-05 | 8.102E-03 | PRKCB, PRKCH, PRKCQ, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 7.199E-05 | 8.122E-03 | AKR1B1, AKR1B10, ALDH1A1, CYP3A4, PPARD |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 8.028E-05 | 8.919E-03 | AKR1B1, ALOX15, FABP4, PRKCD, PTGS2, TERT |
| BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 9.098E-05 | 9.808E-03 | PPARA, PPARG, PTGS1, PTGS2 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 9.289E-05 | 9.964E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, FABP2, FABP3, FABP4, FABP5, HPGD, LMNA, PPARG, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.303E-10 | 7.883E-09 | PRKCG; PRKCH; PRKCB; PRKCE; PRKCD; PRKCA; PRKCQ |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.048E-11 | 1.268E-09 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 5.474E-10 | 2.208E-08 | PRKCG; PRKCH; PRKCB; PRKCE; PRKCD; PRKCA; PRKCQ |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 1.539E-09 | 4.655E-08 | PRKCG; PRKCH; PRKCB; PRKCE; PRKCD; PRKCA; PRKCQ |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.770E-08 | 4.283E-07 | PRKCG; PRKCB; ALOX15; PRKCA; PTGS2; PTGS1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 4.550E-07 | 7.865E-06 | PRKCG; FAAH; PRKCB; PRKCA; PTGS2 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 3.011E-07 | 6.073E-06 | PRKCG; PRKCB; PRKCE; PRKCD; PRKCA |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.653E-07 | 1.006E-05 | PRKCB; PRKCE; PRKCD; PRKCQ; PPARA |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.639E-06 | 2.204E-05 | FABP4; PTGS2; TSHR; PTGS1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.317E-06 | 2.803E-05 | PRKCG; PRKCB; PRKCA; PTGS2 |
| hsa04925 | Aldosterone synthesis and secretion_Homo sapiens_hsa04925 | 7.228E-06 | 7.288E-05 | PRKCG; PRKCB; PRKCE; PRKCA |
| hsa04918 | Thyroid hormone synthesis_Homo sapiens_hsa04918 | 4.267E-06 | 4.694E-05 | PRKCG; PRKCB; PRKCA; TSHR |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.736E-05 | 1.400E-04 | PRKCB; PRKCE; PRKCD; PRKCA |
| hsa04911 | Insulin secretion_Homo sapiens_hsa04911 | 8.758E-06 | 8.152E-05 | PRKCG; PRKCB; PRKCA; FFAR1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.849E-05 | 1.995E-04 | PRKCG; PRKCB; PRKCA; PPARG; PTGS2; PPARD |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.669E-05 | 1.400E-04 | PRKCG; PRKCB; PRKCA; TLR2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.421E-05 | 2.179E-04 | PRKCG; PRKCB; PRKCE; PRKCA |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.356E-05 | 4.046E-04 | PRKCG; PRKCB; PRKCA; TLR2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 6.603E-05 | 3.805E-04 | PRKCG; PRKCB; PRKCA; PPARD |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.643E-05 | 4.457E-04 | PRKCG; PRKCB; PRKCE; PRKCA; PTGS2 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 9.991E-05 | 4.835E-04 | PRKCG; PRKCB; PRKCA; PTGS2 |
| hsa05143 | African trypanosomiasis_Homo sapiens_hsa05143 | 2.134E-05 | 1.614E-04 | PRKCG; PRKCB; PRKCA |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | 5.220E-05 | 3.158E-04 | PRKCG; PRKCB; PRKCA |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 8.841E-05 | 4.457E-04 | PRKCG; PRKCB; PRKCA |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.967E-05 | 1.995E-04 | PRKCG; PRKCB; PRKCA |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.615E-04 | 9.308E-04 | PRKCG; PRKCB; PRKCA; TLR2 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.087E-04 | 4.870E-04 | PRKCG; PRKCB; PRKCA |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.380E-04 | 5.758E-04 | PRKCG; PRKCB; PRKCA |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.087E-04 | 4.870E-04 | PRKCG; PRKCB; PRKCA |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 1.510E-04 | 5.895E-04 | PRKCG; PRKCB; PRKCA |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.199E-04 | 5.180E-04 | ALOX15; PTGS2; PTGS1 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.029E-04 | 7.439E-04 | PRKCG; PRKCB; PRKCA |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 1.444E-04 | 5.825E-04 | PRKCG; PRKCB; PRKCA |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.949E-04 | 7.368E-04 | PRKCB; PTGS2; TLR2 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.272E-04 | 1.107E-03 | PRKCG; PRKCB; PRKCA |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 3.384E-04 | 1.107E-03 | PRKCG; PRKCB; PRKCA |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 3.735E-04 | 1.130E-03 | PRKCB; PRKCD; PRKCA |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 3.735E-04 | 1.130E-03 | PRKCG; PRKCB; PRKCA |
| hsa04970 | Salivary secretion_Homo sapiens_hsa04970 | 3.499E-04 | 1.114E-03 | PRKCG; PRKCB; PRKCA |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.384E-04 | 1.107E-03 | PRKCG; PRKCB; PRKCA |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 4.238E-04 | 1.221E-03 | PRKCG; PRKCB; PRKCA |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 4.925E-04 | 1.324E-03 | PRKCG; PRKCB; PRKCA |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 6.678E-04 | 1.683E-03 | PRKCG; PRKCB; PRKCA |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.070E-04 | 1.334E-03 | PRKCG; PRKCB; PRKCA |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.981E-04 | 1.175E-03 | PRKCB; PRKCQ; PTGS2 |
| hsa04070 | Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | 4.642E-04 | 1.276E-03 | PRKCG; PRKCB; PRKCA |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.369E-04 | 1.382E-03 | PRKCG; PRKCB; PRKCA |
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 7.217E-04 | 1.782E-03 | PRKCG; PRKCB; PRKCA |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 4.370E-04 | 1.230E-03 | PRKCG; PRKCB; PRKCA |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.977E-04 | 1.893E-03 | PRKCG; PRKCB; PRKCA |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.432E-03 | 5.073E-03 | AKR1B10; ALOX15; ALDH1A1; AKR1B1; PTGS2; CYP3A4; PTGS1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 7.977E-04 | 1.893E-03 | PRKCG; PRKCB; PRKCA |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.033E-03 | 2.314E-03 | PRKCG; PRKCB; PRKCA |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.177E-03 | 2.544E-03 | PRKCG; PRKCB; PRKCA |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 2.677E-03 | 5.399E-03 | PRKCG; PRKCB; PRKCA |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 3.705E-03 | 7.349E-03 | PRKCG; PRKCB; PRKCA |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.186E-03 | 8.039E-03 | PRKCG; PRKCB; PRKCA |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 5.131E-03 | 9.551E-03 | PRKCG; PRKCB; PRKCA |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 7.074E-03 | 1.272E-02 | PRKCG; PRKCB; PRKCA |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.876E-02 | 3.290E-02 | PRKCQ; TLR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.149E-03 | 1.272E-02 | CYP3A4; PTGS2 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 5.259E-03 | 9.641E-03 | PRKCQ; PPARA |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.551E-03 | 8.604E-03 | ALDH1A1; CYP3A4 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 3.765E-03 | 7.349E-03 | AKR1B10; AKR1B1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.509E-03 | 5.145E-03 | PRKCE; PRKCD |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 9.844E-04 | 2.247E-03 | AKR1B10; AKR1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.197E-04 | 2.140E-03 | ALOX15; CYP3A4 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.417E-03 | 3.009E-03 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.120E-03 | 2.465E-03 | AKR1B10; AKR1B1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | PRKCE |
| C00-D49: Neoplasms | Central nervous system tumors | NA | PRKCB |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| I00-I99: Diseases of the circulatory system | Ischemic reperfusion injury | I00-I99 | PRKCE |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; PPARG; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; FAAH; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PRKCQ; PTGS1; FAAH; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | PRKCB |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | PRKCB |
| NA: NA | Reperfusion injury and heart attacks | NA | PRKCD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | PRKCB |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; NR1I2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PTGS2; PPARG; PPARG |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PTGS2; PPARG |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PPARG |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | PRKCB; TERT |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Cancer | C00-C96 | PRKCB; TLR2; PTGS2 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| I00-I99: Diseases of the circulatory system | Acute myocardial infarction | I21-I22 | PRKCD |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | PRKCB |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |